ASND β€” ASCENDIS PHARMA A S

Ownership history in Ghost Tree Capital, LLC  Β·  32 quarters on record

This page tracks every 13F SEC filing in which Ghost Tree Capital, LLC reported a position in ASCENDIS PHARMA A S (ASND). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β€” sourced directly from SEC EDGAR 13F filings.

πŸ” Peak position
12.28% (2019 Q1)
πŸ“Š Avg. % of fund
3.72%
πŸ“… First filed
2015 Q2
πŸ“… Last filed
2024 Q3
⏱ Quarters held
32

Position Intelligence

Ghost Tree Capital, LLC Γ— ASND AI Analytics

πŸ“ˆ Ghost Tree Capital, LLC outperformed the S&P 500 by +29.8% annually on this ASND position. Timing score: 47% (14/30 decisions correct). Average cost basis: $96.91. Maximum drawdown during holding period: –46.5%.

πŸ“ˆ Position Alpha vs SPY
+29.8%
annualised excess return

πŸ”₯ Exceptional β€” beat the S&P 500 by 29.8% per year on this position.
31 quarters analyzed

⏱️ Timing Score
47%

➑️ Neutral timing β€” roughly coin-flip accuracy on add/trim calls.
14 of 30 add/trim decisions correct

πŸ’° Entry Quality
$96.91
+54.1% vs current ($149.31)

Best entry: $13.27 (2016 Q2)  Β·  Worst: $154.32 (2020 Q3)

πŸ›‘οΈ Drawdown Resilience
–46.5%
max drawdown while held

πŸ’ͺ Held through 3 major drawdowns (>20%). Diamond-hands conviction.

πŸ’ͺ Fund Conviction
52%
buy-side decisions

16 adds Β· 15 trims. Bought during 4 of 11 down-price quarters. πŸ“ˆ More buys than sells across the holding period.

πŸ“‘ Position Trajectory
↑ Growing
last 4–5 quarters trend

πŸ“ˆ Ghost Tree Capital, LLC has been actively increasing its ASND allocation β€” a bullish signal from insiders.
Currently 2.37% of portfolio

⚠ Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ— 4 (annualised). Not investment advice.

% of Fund (quarterly)    ASND price (monthly, adj. close)
πŸ“‹ Quarterly Holdings History 10 quarters  β–Ύ
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2024 Q3 REDUCED 52,500 -34,221 -39.5% 2.37% $7.8M $149.31
2024 Q2 ADDED 86,721 +66,721 +333.6% 3.70% $11.8M $136.38
2023 Q4 REDUCED 20,000 -65,000 -76.5% 0.82% $2.5M $125.95
2023 Q3 REDUCED 85,000 -15,000 -15.0% 2.62% $8.0M $93.64
2023 Q2 REDUCED 100,000 -10,000 -9.1% 2.95% $8.9M $89.25
2023 Q1 REDUCED 110,000 -20,000 -15.4% 3.49% $11.8M $107.22
2022 Q4 ADDED 130,000 +35,000 +36.8% 6.78% $15.9M $122.13
2022 Q3 ADDED 95,000 +20,000 +26.7% 2.75% $9.8M $103.26
2022 Q2 REDUCED 75,000 -65,000 -46.4% 3.63% $7.0M $92.96
2022 Q1 REDUCED 140,000 -50,000 -26.3% 3.57% $16.4M $117.36
22 older quarters hidden  β€”  Sign in free or upgrade to Premium to see full history

🏒 Other funds also holding ASND

As of 2025 Q4 β€” sorted by position size

Q Global Advisors, LLC 3Y 7Y 39.86% RA CAPITAL MANAGEMENT, L.P. 3Y 7Y 22.46% Avoro Capital Advisors LLC 3Y 7Y 10.71% Resolute Capital Asset Partners LLC 3Y 9.13% Tri Locum Partners LP 3Y 7.34% WESTFIELD CAPITAL MANAGEMENT CO LP 3Y 7Y 4.61% Catalio Capital Management, LP 4.49% Spyglass Capital Management LLC 3Y 7Y 4.43% PERCEPTIVE ADVISORS LLC 3Y 7Y 4.11% PFM Health Sciences, LP 3Y 7Y 3.78%
← Back to Ghost Tree Capital, LLC Holdings